Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (CA2921410) CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS

Office : Canada
Application Number: 2921410 Application Date:
Publication Number: 2921410 Publication Date: 26.02.2015
Publication Kind : A1
Prior PCT appl.: Application Number:PCTUS2014052409 ; Publication Number: Click to see the data
IPC:
C07D 471/04
A61K 31/517
A61K 31/5377
A61P 35/00
C07D 239/42
C07D 401/12
C07D 403/12
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
471
Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/-C07D463/251
02
in which the condensed system contains two hetero rings
04
Ortho-condensed systems
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
495
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
517
ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
535
having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
5375
1,4-Oxazines, e.g. morpholine
5377
not condensed and containing further heterocyclic rings, e.g. timolol
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
239
Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
02
not condensed with other rings
24
having three or more double bonds between ring members or between ring members and non-ring members
28
with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
32
One oxygen, sulfur or nitrogen atom
42
One nitrogen atom
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
401
Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
02
containing two hetero rings
12
linked by a chain containing hetero atoms as chain links
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
403
Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/167
02
containing two hetero rings
12
linked by a chain containing hetero atoms as chain links
CPC:
A61K 31/517
Applicants: NEUPHARMA, INC.
Inventors:
Priority Data: 61/869,596 23.08.2013 US
61/900,283 05.11.2013 US
62/000,946 20.05.2014 US
Title: (EN) CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS
(FR) ENTITES CHIMIQUES, COMPOSITIONS ET METHODES PARTICULIERES
Abstract:
(EN) Chemical entities that are effective as kinase inhibitors, pharmaceutical compositions and methods of treatment are disclosed. The chemical entities disclosed specifically inhibit signal transduction and cellular proliferation by modulating the activity of protein kinases to regulate and modulate abnormal or inappropriate cell proliferation, differentiation, or metabolism. The compounds include a pyrido[3,2-d]pyrimidine scaffold substituted with aromatic and heteroaromatic moieties.


Also published as:
SG11201601138PIL244189EP3035936CN105682661KR1020160090786JP2016530274
US20170050936AU2014308616MYPI 2016000328PH1/2016/500330BR112016005199RU2016110412
IN201617005602WO/2015/027222